Alnylam said the green light makes Amvuttra the first and only RNAi therapeutic approved in Europe for the treatment of the cardiomyopathy manifestations of ATTR amyloidosis and the polyneuropathy ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted approval for the treatment of wild ...

BridgeBio's Attruby surpasses expectations with booming Q1 revenue and strong market positioning. Read why BBIO stock is ...

There are many types of amyloidosis. Amvuttra (vutrisiran) is used to treat two kinds of amyloidosis. The first is known as hereditary transthyretin-mediated amyloidosis (hATTR) with ...

As multiple companies vie to expand on Alnylam’s success in commercializing RNAi therapeutics, the pioneering company has set ...

The world just got a little closer. The new iGlobal Radio App is now live, offering users a dynamic way to connect with radio ...

Morningstar brands and products Company Portfolio ...

Analysis Presented at the Heart Failure 2025 Congress Supports Primary Findings, Highlighting Impact of AMVUTTRA, which Delivers Rapid Knockdown of Transthyretin – – Additional 42-Month Data ...

Spinal Simplicity, a medical device company dedicated to creating simple, innovative procedure solutions, is proud to announce the launch of the Patriot-SI implant as a stand-alone solution for ...

The recent approval and launch of Amvuttra for ATTR-CM represent a significant milestone for Alnylam. The drug received early approval with a broad label, which is considered a strong positive for ...